REFRACTORY MALIGNANT SOLID NEOPLASM
Clinical trials for REFRACTORY MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for REFRACTORY MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Anusha Kalbasi • Aim: Disease control
Last updated May 16, 2026 22:31 UTC
-
New drug TAK-243 targets cancer cells in early trial
Disease control Recruiting nowThis early-phase study tests the safety and best dose of TAK-243, a drug that targets a protein cancer cells need to grow. About 95 adults with advanced solid tumors or lymphoma that hasn't responded to standard treatments will take part. The goal is to find side effects and the …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 22:31 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The trial includes up to 49 participants,…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 16, 2026 22:28 UTC
-
New drug targets Cancer's fuel pump in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called MTI-301 in about 42 adults with advanced solid cancers that have spread or not responded to standard treatments. MTI-301 blocks an enzyme (SCD1) that helps tumors grow. The main goals are to find the safest dose and check for side ef…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New Triple-Drug cocktail aims to shrink tough cancers
Disease control Recruiting nowThis study tests whether combining three drugs—axatilimab, retifanlimab, and paclitaxel—is safe and works against advanced or metastatic solid tumors. About 38 adults with tumors that have spread will receive the combination. The goal is to find the best dose and see if the treat…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for kids with Hard-to-Treat cancers: Two-Drug attack on tumors
Disease control Recruiting nowThis study is for children and young adults whose solid tumors have come back or not gone away. It tests two different drug pairs that damage cancer cell DNA to kill the tumor. The goal is to find the best dose and see if the treatment can shrink or stop the cancer.
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for kids with relapsed cancers: experimental drug CBL0137 enters trials
Disease control Recruiting nowThis study tests an experimental drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors by …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for young cancer patients: drug duo targets resistant tumors
Disease control Recruiting nowThis study tests a new drug combination (DT2216 plus irinotecan) in children, teens, and young adults whose solid tumors have returned or not responded to treatment. The goal is to find the safest dose and see if the combo can shrink tumors, especially in a rare liver cancer call…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
New hope for tough cancers: first human trial of AOH1996 begins
Disease control Recruiting nowThis early-stage study is testing a new drug, AOH1996, in adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and understand side effects. The drug works by blocking certai…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New drug AU409 enters first human tests for tough liver cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called AU409 in people with advanced liver cancer or other cancers that have spread to the liver. The main goals are to find the safest dose and see what side effects occur. About 36 adults whose cancer has not responded to standard treatme…
Matched conditions: REFRACTORY MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC